Stiolto Respimat (Tiotropium bromide/Olodaterol) for COPD

Overview
Stiolto Respimat is a prescription drug approved by the Food and Drug Administration (FDA) as long-term, once-daily maintenance treatment for airflow obstruction in people with chronic obstructive pulmonary disease (COPD). Stiolto Respimat is a combination drug composed of Tiotropium bromide and Olodaterol.

Tiotropium bromide is an anticholinergic. Olodaterol is a long-acting beta2-adrenergic agonist (LABA). Both drugs are long-acting bronchodilators. Both drugs are believed to work by relaxing and dilating the airways, making it easier to breathe.

How do I take it?
Stiolto Respimat is taken once daily.

Stiolto Respimat comes in the form of an inhalation spray packaged in the special Respimat device.

Side effects
The FDA-approved label for Stiolto Respimat lists common side effects including cold symptoms, cough, and back pain.

Rare but serious side effects listed for Stiolto Respimat can include paradoxical bronchospasm (bronchospasm caused by taking medication), worsening narrow-angle glaucoma or urinary retention, changes in blood glucose or electrolyte levels, hypersensitivity reaction, and an increased risk for asthma-related death.

For more details about this treatment, visit:

Stiolto – Boehringer Ingelheim
https://www.stiolto.com/